Proprietary laboratory analyses (ending in U): Federal IDR outcomes by code
| CPT code | Line items | Win % | Median ×QPA | Ratio n | Median days |
|---|---|---|---|---|---|
| 0202U Test for detection of respiratory disease-causing organisms from back of nose an | 8,218 | 75.1% | 7.13x | 5,617 | – |
| 0241U Respiratory infectious agent detection by RNA for severe acute respiratory syndr | 1,260 | 80.1% | 2.00x | 688 | – |
| 0240U Respiratory infectious agent detection by RNA for severe acute respiratory syndr | 367 | 55.9% | 6.12x | 31 | – |
| 0351U Biochemical assays for markers of bacterial infection | 189 | 87.8% | 6.29x | 189 | – |
| 0340U DNA assays for detection of minimal residual disease in cancer | 168 | 76.8% | 1.00x | 157 | – |
| 0326U Targeted genomic sequence analysis of 83 or more genes in cell free circulating | 88 | 77.3% | 1.00x | 87 | – |
| 0242U Gene analysis of 55-74 genes associated with solid organ cancer in cell-free cir | 51 | 68.6% | 1.00x | 51 | – |
2023 Q1–2025 Q4 · rows with n ≥ 30 determined line items · sorted by n.
Dollar amounts by code
| CPT code | Line items with $ | Total awarded | Median award | Median QPA | Award ×QPA |
|---|---|---|---|---|---|
| 0202U Test for detection of respiratory disease-causing organisms from back of nose an | 3,824 | $18.1M | $6,809 | $446 | 7.15x |
| 0241U Respiratory infectious agent detection by RNA for severe acute respiratory syndr | 601 | $409,541 | $506 | $244 | 1.84x |
| 0351U Biochemical assays for markers of bacterial infection | 117 | $93,982 | $700 | $139 | 5.94x |
| 0340U DNA assays for detection of minimal residual disease in cancer | 85 | $259,398 | $3,590 | $3,590 | 0.85x |
| 0326U Targeted genomic sequence analysis of 83 or more genes in cell free circulating | 69 | $505,669 | $9,650 | $9,650 | 0.88x |
2024 Q3–2025 Q4 · CMS QPA and Offers file · rows with n ≥ 30 line items with dollar amounts · sorted by n · Award ×QPA = total awarded ÷ total QPA.